Who is going to take over the reigns of the healthcare industry once and for all? Will it be Amazon who seems to dominate in any field they participate in? Could CVS best them by showing that legacy players still have something to offer to customers when you boil it down?
Those are the types of questions that have been burning in the minds of many observers of the healthcare industry. Drew Madden is one of those observers. He has to be given the nature of the work that he does. Drew is a healthcare information technology entrepreneur. This means that Drew Madden does like to keep his finger on the pulse of what is happening in the market as a whole.
Everyone would like a simple answer on which of these two companies has the best chance of winning over the most customers. The reality though is that both have adopted unique strategies which will probably serve them well. It is entirely possible that both companies end up in a place that is better than where they started. For more details visit Bloomberg.
The move is obvious for Amazon. They have decided that they would like to join the healthcare industry. They have been applying for licenses to sell healthcare related products in certain states. For them, it is just an obvious expansion move.
CVS has taken on a bit of a different strategy when it comes to how they will work the industry. What they are doing has more to do with shoring up their position as an industry leader in the first place. They were already part of the industry to begin with. Therefore, the only thing that they can do differently is try to gain even more ground in a business that they are a major player in.
The task is one of building out more on the business model that they already have. The purchase of healthcare insurance giant Aetna makes a lot of sense for CVS given that they would like to control the marketshare of customers from start to finish. Owning an insurance company definitely helps them do exactly that. Check out hudl.com
Click here: https://www.crunchbase.com/person/drew-madden#/entity
In the beginning of the year in 2002 a bio-pharmaceutical company was founded in Cranbury, New Jersey. That company is called Amicus Therapeutics which also has roughly one hundred employees currently working for it. Amicus Therapeutics and in the year 2007 Amicus went public and started trading on the NASDAQ Under the symbol FOLD. With steady growth Amicus Therapeutics opened a second location in San Diego, California. So with two locations on both coasts Amicus Therapeutics will have its focus on the main goal of the company which deals with rare and orphan diseases with particular disorders called lysosomal storage disorders.
With the saying “WE ARE PASSIONATE ABOUT WHAT WE DO“, this global biotechnological company is at the forefront of helping patients with Fabry Disease,Pompe Disease and others. The onset of Fabry Disease will shorten a persons life at approximately by fifty years. Pompe Disease is a lysosomal storage disorder which is diagnosed shortly after the birth of a child which includes the enlargement of the heart and muscle weakness. The late onset of Pompe Disease will not appear until late childhood or early adulthood. It is known that Pompe Disease affects aproximately 5,000 to 10,000 people worldwide.
Amicus is at the forefront of helping patients and their families with their dedication of helping with its services just beyond these horrible diseases. They listen and learn from the patients and families that are affected by these diseases. Amicus is always looking for better ways to help those afflicted by those diseases. Give information and the resources for families to fight the disease that one of their family members suffer with. At this time Amicus is in the middle of developing processes to help families cope with these terrible diseases. Amicus Therapeutic also wants to be involved in the education and support of families cope with these devastating diseases.
Find out more about Amicus Therapeutics: